Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
5.1
-33.14%
40%
—
24.46%
80%
—
5 Years
Score5.1
Net Growth-33.14%
Net Trend40%
Net Income Consistency—
Rev Growth24.46%
Rev Trend80%
Revenue Consistency—
Edwards Lifesciences Corp fundamental performance
Between 2015 and 2025, revenue grew from $ 2.49B to $ 6.06B and net income grew from $ 494M to $ 1.07B. Revenue increased in 9 of those 10 years; net income in 6.
Between 2005 and 2025, revenue grew from $ 997M to $ 6.06B and net income grew from $ 79M to $ 1.07B. Revenue increased in 19 of those 20 years; net income in 13.
Edwards Lifesciences Corp currently holds a 20-year HDB Score of 8.0 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 93.05 | — |
1 Year2025-08-12 | $ 76.93 | 20.95% |
5 Years2021-08-12 | $ 111.77 | -16.75% |
10 Years2016-08-12 | $ 37.87 | 145.73% |
20 Years2006-08-11 | $ 3.77 | 24x |
All Time2000-03-27 | $ 1.38 | 67x |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | 10 Years2016-08-12 | 20 Years2006-08-11 | All Time2000-03-27 |
|---|---|---|---|---|---|---|
| Price | $ 93.05 | $ 76.93 | $ 111.77 | $ 37.87 | $ 3.77 | $ 1.38 |
| Return | — | 20.95% | -16.75% | 145.73% | 24x | 67x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 6.51B | $ 1.00B | |
| 2025 | $ 6.06B | $ 1.07B | $ 4.22B |
| 2024 | $ 5.43B | $ 4.17B | $ 3.97B |
| 2023 | $ 6.00B | $ 1.40B | $ 1.63B |
| 2022 | $ 5.38B | $ 1.52B | $ 1.21B |
| 2021 | $ 5.23B | $ 1.50B | $ 1.46B |
| 2020 | $ 4.38B | $ 823M | $ 1.40B |
| 2019 | $ 4.34B | $ 1.04B | $ 1.51B |
| 2018 | $ 3.72B | $ 722M | $ 956M |
| 2017 | $ 3.43B | $ 622M | $ 1.33B |
| 2016 | $ 2.96B | $ 569M | $ 1.27B |
| 2015 | $ 2.49B | $ 494M | $ 1.22B |
| 2014 | $ 2.32B | $ 811M | $ 1.43B |
| 2013 | $ 2.04B | $ 391M | $ 936M |
| 2012 | $ 1.89B | $ 293M | $ 521M |
| 2011 | $ 1.67B | $ 236M | $ 450M |
| 2010 | $ 1.44B | $ 218M | $ 396M |
| 2009 | $ 1.32B | $ 229M | $ 334M |
| 2008 | $ 1.23B | $ 128M | $ 226M |
| 2007 | $ 1.09B | $ 113M | $ 191M |
| 2006 | $ 1.03B | $ 130M | $ 182M |
| 2005 | $ 997M | $ 79M | $ 178M |
| 2004 | $ 931M | $ 1M | $ 48M |
| 2003 | $ 860M | $ 79M | $ 61M |
| 2002 | $ 704M | $ 55M | $ 34M |
| 2001 | $ 692M | -$ 12M | $ 48M |
| IPO2000 | $ 804M | -$ 272M | $ 28M |
Explore beyond EW
You're looking at Edwards Lifesciences Corp. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
Explore other companies
- Mettler-Toledo International IncMTD· revenue grew in 85% of years
- UFP Technologies IncUFPT· revenue grew in 80% of years
- West Pharmaceutical Services IncWST· revenue grew in 90% of years
- UnitedHealth Group IncorporatedUNH· revenue grew in 100% of years
- Regeneron Pharmaceuticals IncREGN· revenue grew in 90% of years
